What alternative treatments are available for an older adult with polymyalgia rheumatica who cannot tolerate or wishes to avoid long‑term glucocorticoids?

Alternative Treatments for Polymyalgia Rheumatica in Glucocorticoid-Intolerant Patients

For older adults with PMR who cannot tolerate or wish to avoid long-term glucocorticoids, methotrexate (7.5-10 mg/week) should be added as first-line glucocorticoid-sparing therapy, with tocilizumab or sarilumab reserved for patients who fail methotrexate or have high-risk comorbidities making any glucocorticoid exposure dangerous. 1

Primary Glucocorticoid-Sparing Agent: Methotrexate

Methotrexate remains the only conditionally recommended conventional DMARD for PMR and should be considered early in the following situations: 1

• Patients with comorbidities where glucocorticoid-related adverse events are particularly dangerous: diabetes, osteoporosis with recent fractures, glaucoma, uncontrolled hypertension, cardiovascular disease, or chronic infections 1
• Patients at high risk for relapse or prolonged therapy: female sex, presence of peripheral inflammatory arthritis, or high baseline ESR (>40 mm/hour) 1
• Patients experiencing glucocorticoid-related adverse events during treatment 1
• Patients with disease relapse or inadequate response to glucocorticoids 1

The evidence for methotrexate shows conflicting results in clinical trials, but the EULAR/ACR guidelines conditionally recommend it based on its glucocorticoid-sparing potential. 1 Methotrexate has been studied at oral doses of 7.5-10 mg/week in PMR trials. 1

Biologic Therapy: IL-6 Receptor Antagonists

Tocilizumab

Tocilizumab is the most robustly studied biologic for PMR and has demonstrated superior efficacy compared to placebo in achieving sustained remission and reducing glucocorticoid burden. 1, 2, 3

• Tocilizumab achieved higher remission rates and better glucocorticoid-sparing effects than placebo in phase III trials for GCA (where it is FDA-approved) and phase II/III trials for PMR (not yet approved for this indication). 1
• It should be considered for glucocorticoid-resistant PMR (patients who respond poorly to initial 15 mg/day prednisolone or experience flares during tapering to ≤5 mg/day). 4
• Tocilizumab is particularly valuable for patients with steroid-resistant disease or at high risk of glucocorticoid complications. 3, 5

Important caveat: Neither tocilizumab nor methotrexate has been associated with a reduction in glucocorticoid-related adverse outcomes in studies to date, though they reduce cumulative glucocorticoid exposure. 1

Sarilumab

Sarilumab (another IL-6 receptor antagonist) showed higher efficacy than placebo in achieving sustained remission in a phase III trial that was terminated early due to COVID-19. 1 Preliminary results are promising, and it represents an emerging alternative to tocilizumab. 2, 3, 5

Alternative Glucocorticoid Formulation

Intramuscular methylprednisolone (120 mg every 3 weeks initially) can be considered as an alternative to oral glucocorticoids in patients where lower cumulative glucocorticoid exposure is desirable, particularly women with difficult-to-control hypertension, diabetes, osteoporosis, or glaucoma. 1

However, this recommendation is conditional because: 1

• Only one randomized controlled trial supports its use
• The trial failed to demonstrate reduction in glucocorticoid-related adverse events except for weight gain
• Long-term benefits are unknown
• It is not available in all countries

Non-Pharmacologic Interventions

An individualized exercise program should be implemented to maintain muscle mass and function and reduce fall risk, especially critical in older persons on long-term glucocorticoids and frail patients. 1

Treatments to Avoid

TNF-α blocking agents are strongly recommended against for treatment of isolated PMR, as they have shown no efficacy. 1, 3

Chinese herbal preparations (Yanghe and Biqi capsules) are strongly recommended against for PMR patients. 1

Clinical Algorithm for Glucocorticoid-Intolerant Patients

1. If patient has absolute contraindication to glucocorticoids or severe intolerance:

   • Consider tocilizumab as monotherapy (off-label for PMR) 4, 5
   • Requires rheumatology referral 1, 5

2. If patient can tolerate minimal glucocorticoid exposure:

   • Start lowest effective glucocorticoid dose (12.5 mg prednisone equivalent) 1
   • Add methotrexate 7.5-10 mg/week immediately 1
   • Consider intramuscular methylprednisolone if oral route problematic 1

3. If methotrexate fails or patient develops glucocorticoid toxicity:

   • Add tocilizumab or sarilumab 1, 2, 3, 5
   • Requires rheumatology consultation 5

4. Monitor closely:

   • Every 4-8 weeks in first year 1
   • Assess disease activity, inflammatory markers, and adverse events at each visit 1

Common Pitfalls

• Do not use NSAIDs as primary therapy for PMR—they are strongly discouraged except for short-term use for pain from other conditions. 1
• Do not delay specialist referral in patients with atypical presentation, high risk of side effects, or glucocorticoid resistance. 1, 5
• Recognize that newer biologics show promise but cost considerations are significant compared to traditional therapies. 2
• Understand that even with biologics, complete avoidance of glucocorticoids may not be possible—the goal is minimization, not elimination. 1, 2, 5